WO1998048031A1 - Procede de production d'adenosine 5'-triphosphate et utilisation de ladite substance - Google Patents
Procede de production d'adenosine 5'-triphosphate et utilisation de ladite substance Download PDFInfo
- Publication number
- WO1998048031A1 WO1998048031A1 PCT/JP1998/001711 JP9801711W WO9848031A1 WO 1998048031 A1 WO1998048031 A1 WO 1998048031A1 JP 9801711 W JP9801711 W JP 9801711W WO 9848031 A1 WO9848031 A1 WO 9848031A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- kinase
- polyphosphate
- adenosine
- atp
- reaction
- Prior art date
Links
- 229960001456 adenosine triphosphate Drugs 0.000 title claims abstract description 58
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 title claims abstract description 57
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims abstract description 19
- 108020000161 polyphosphate kinase Proteins 0.000 claims abstract description 45
- 102000002281 Adenylate kinase Human genes 0.000 claims abstract description 40
- 108020000543 Adenylate kinase Proteins 0.000 claims abstract description 40
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 claims abstract description 34
- 229950006790 adenosine phosphate Drugs 0.000 claims abstract description 34
- UDMBCSSLTHHNCD-UHFFFAOYSA-N Coenzym Q(11) Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(O)=O)C(O)C1O UDMBCSSLTHHNCD-UHFFFAOYSA-N 0.000 claims abstract description 32
- 238000006243 chemical reaction Methods 0.000 claims description 36
- 238000006911 enzymatic reaction Methods 0.000 claims description 20
- 239000001205 polyphosphate Substances 0.000 claims description 18
- 235000011176 polyphosphates Nutrition 0.000 claims description 18
- 229920000388 Polyphosphate Polymers 0.000 claims description 17
- 238000004519 manufacturing process Methods 0.000 claims description 17
- XTWYTFMLZFPYCI-KQYNXXCUSA-N 5'-adenylphosphoric acid Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XTWYTFMLZFPYCI-KQYNXXCUSA-N 0.000 claims description 15
- 150000001875 compounds Chemical class 0.000 claims description 14
- MWEQTWJABOLLOS-UHFFFAOYSA-L disodium;[[[5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-oxidophosphoryl] hydrogen phosphate;trihydrate Chemical compound O.O.O.[Na+].[Na+].C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP([O-])(=O)OP(O)([O-])=O)C(O)C1O MWEQTWJABOLLOS-UHFFFAOYSA-L 0.000 claims description 5
- 150000004712 monophosphates Chemical class 0.000 claims description 2
- 239000001226 triphosphate Substances 0.000 claims 1
- 235000011178 triphosphate Nutrition 0.000 claims 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims 1
- 102000001253 Protein Kinase Human genes 0.000 abstract description 6
- 229920000137 polyphosphoric acid Polymers 0.000 abstract description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 26
- 102000004190 Enzymes Human genes 0.000 description 25
- 108090000790 Enzymes Proteins 0.000 description 25
- 229940088598 enzyme Drugs 0.000 description 25
- 230000000694 effects Effects 0.000 description 23
- 241000588724 Escherichia coli Species 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 17
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 16
- 229910001629 magnesium chloride Inorganic materials 0.000 description 13
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000003786 synthesis reaction Methods 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 9
- 244000005700 microbiome Species 0.000 description 9
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 101150001140 ppk gene Proteins 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 102000048120 Galactokinases Human genes 0.000 description 7
- 108700023157 Galactokinases Proteins 0.000 description 7
- 238000005119 centrifugation Methods 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 239000013612 plasmid Substances 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 6
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 6
- 235000011130 ammonium sulphate Nutrition 0.000 description 6
- 108091008146 restriction endonucleases Proteins 0.000 description 6
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 6
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 229910052816 inorganic phosphate Inorganic materials 0.000 description 5
- 230000000813 microbial effect Effects 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 230000026731 phosphorylation Effects 0.000 description 5
- 102100032534 Adenosine kinase Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- DRBBFCLWYRJSJZ-UHFFFAOYSA-N N-phosphocreatine Chemical compound OC(=O)CN(C)C(=N)NP(O)(O)=O DRBBFCLWYRJSJZ-UHFFFAOYSA-N 0.000 description 4
- 108091000080 Phosphotransferase Proteins 0.000 description 4
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 4
- 229960000723 ampicillin Drugs 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 102000020233 phosphotransferase Human genes 0.000 description 4
- 238000001556 precipitation Methods 0.000 description 4
- 230000001172 regenerating effect Effects 0.000 description 4
- 230000002407 ATP formation Effects 0.000 description 3
- 102000012410 DNA Ligases Human genes 0.000 description 3
- 108010061982 DNA Ligases Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 108010006785 Taq Polymerase Proteins 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 101150045155 adk gene Proteins 0.000 description 3
- HXXFSFRBOHSIMQ-FPRJBGLDSA-N alpha-D-galactose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H]1O HXXFSFRBOHSIMQ-FPRJBGLDSA-N 0.000 description 3
- 238000000137 annealing Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 229930182830 galactose Natural products 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000008929 regeneration Effects 0.000 description 3
- 238000011069 regeneration method Methods 0.000 description 3
- 239000012134 supernatant fraction Substances 0.000 description 3
- 230000002194 synthesizing effect Effects 0.000 description 3
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 2
- 230000004544 DNA amplification Effects 0.000 description 2
- 101900338673 Escherichia coli Polyphosphate kinase Proteins 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 238000000246 agarose gel electrophoresis Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 239000013611 chromosomal DNA Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000000287 crude extract Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000004925 denaturation Methods 0.000 description 2
- 230000036425 denaturation Effects 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229950007002 phosphocreatine Drugs 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000012137 tryptone Substances 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- XTWYTFMLZFPYCI-UHFFFAOYSA-N Adenosine diphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(O)=O)C(O)C1O XTWYTFMLZFPYCI-UHFFFAOYSA-N 0.000 description 1
- 102100037293 Atrial natriuretic peptide-converting enzyme Human genes 0.000 description 1
- 101710133555 Atrial natriuretic peptide-converting enzyme Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101900137526 Escherichia coli Galactokinase Proteins 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 101100062121 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) cyc-1 gene Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108020000553 UMP kinase Proteins 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 238000005576 amination reaction Methods 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 229940079919 digestives enzyme preparation Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hcl hcl Chemical compound Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K potassium phosphate Substances [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
- C12P19/26—Preparation of nitrogen-containing carbohydrates
- C12P19/28—N-glycosides
- C12P19/30—Nucleotides
- C12P19/32—Nucleotides having a condensed ring system containing a six-membered ring having two N-atoms in the same ring, e.g. purine nucleotides, nicotineamide-adenine dinucleotide
Definitions
- the present invention provides a method for producing adenosine 5′-triphosphate (ATP) by reacting adenosine 5′-monophosphate (AMP) with polyphosphate kinase, adenylate kinase and polyphosphate. It is about its application.
- ATP adenosine 5′-triphosphate
- AMP adenosine 5′-monophosphate
- ATP is required as an energy donor or a phosphate donor.
- ATP is supplied from the organism of the microorganism used, but in enzymatic methods, ATP must be added to the reaction system or an efficient ATP regeneration system must be developed. Is essential.
- ATP is synthesized from AMP or adenine using a chemical synthesis method or a microorganism or yeast.
- an inexpensive method for synthesizing ATP has not been established at present, and commercially available ATP is extremely expensive.
- an object of the present invention is to provide a method for producing or regenerating expensive ATP more efficiently than AMP. Disclosure of the invention
- the present inventors have conducted studies to achieve the above object, and found that the activity of synthesizing ATP from AMP by coupling to adenylate kinase in the presence of polyphosphate kinase And completed the present invention.
- the present invention provides a method for producing adenosine 5'-triphosphate, which comprises reacting adenosine 5'-monophosphate with polyphosphate kinase, adenylate kinase and polyphosphate. Is what you do.
- the present invention provides a method for producing a compound using an enzymatic reaction consuming adenosine 5'-triphosphate, wherein adenosine 5'-monophosphate is replaced by polyphosphate kinase, adenylate kinase and polylysine.
- a process for producing the compound characterized in that adenosine 5′-triphosphate is produced by the action of an acid and supplied to the enzyme reaction.
- the present invention provides a method for producing a compound using an enzymatic reaction consuming adenosine 5'-triphosphate, wherein the produced adenosine 5'-phosphate and Z or adenosine 5'-diphosphate are produced.
- a method for producing the compound characterized in that the enzyme reaction is carried out while adenosine 5'-triphosphate is regenerated by reacting polyphosphate kinase, adenylate kinase and polyphosphate with the enzyme. Is what you do.
- the present invention relates to an adenosine 5'-to adenosine 5'-triamine comprising a combination of polyphosphate kinase, adenylate kinase and polyphosphate.
- the present invention provides a system for synthesizing an acid.
- FIG. 1 shows changes in AMP, ADP, and ATP in the ATP synthesis system of the present invention.
- the polyphosphate kinase (EC 2.7.4.1) and adenylate kinase (EC 2.7.4.3) used in the present invention are both known enzymes, and are derived from animals, plants and microorganisms. Those of origin and the like can be used. Among them, microorganisms, particularly Escherichia coli-derived polyphosphate kinase and adenylate kinase, are advantageous in terms of ease of enzyme preparation and the like.
- the polyphosphate kinase gene or adenylate kinase gene is cloned using recent gene recombination technology, and polyphosphate kinase or adenylate kinase is mass-produced using E. coli or the like as a host. It is also possible to prepare the above two types of enzymes respectively (J. Biol. Chem., 267, 22556-22561 (1992), Nucleic Acids Res., 13, 7139-7151 (1985)).
- the polyphosphate kinase and adenylate kinase added to the reaction system may be in any form as long as they have the activity.
- the preparation of the cells of the c microorganism which can be exemplified by the cells of the microorganism, the processed product of the cell, or the enzyme preparation obtained from the processed product, is performed by using a medium in which the microorganism can grow. It can be carried out by a conventional method, followed by culturing by a conventional method, and collecting cells by centrifugation or the like.
- bacteria belonging to the genus Bacillus or E. coli are described as examples.
- the culture medium is bouillon medium, LB medium (1% tryptone, 0.5% yeast extract, 1% salt) or 2XYT A medium (1.6% tryptone, 1% yeast extract, 0.5% salt) can be used.
- LB medium 1% tryptone, 0.5% yeast extract, 1% salt
- 2XYT A medium (1.6% tryptone, 1% yeast extract, 0.5% salt) can be used.
- the treated cells of the microorganisms can be obtained by mechanically crushing the above microorganisms (using a ring blender, French press, homogenizer, mortar, etc.), freeze-thawing, self-digesting, drying (freeze-drying, air-drying, etc.) ), Enzyme treatment (eg, with lysozyme), ultrasonic treatment, chemical treatment (eg, with acid or alkali treatment), etc.
- Enzyme treatment eg, with lysozyme
- ultrasonic treatment eg, with acid or alkali treatment
- chemical treatment eg, with acid or alkali treatment
- a fraction having polyphosphoric acid kinase activity or adenylate kinase activity from the above treated cells is purified by a conventional enzyme purification method (salt-out treatment, isoelectric point precipitation treatment, organic solvent precipitation treatment). , Dialysis, various types of chromatography, etc.).
- AMP can be used for the present invention.
- concentration used eg if 1 to 2 0 O mM, preferably. 1 to 5 0 mM range c and may be appropriately set from, polyphosphate can be used a commercially available added.
- concentration used can be appropriately set, for example, in the range of 1 to 100 mM, preferably 10 to 100 mM in terms of inorganic phosphoric acid.
- ATP can be produced by, for example, adding AMP and polyphosphoric acid to an appropriate buffer having a pH in the range of 4 to 9, and further adding 0.001 units or more, preferably 0.01 to 1 unit. 0.1 units of polyphosphate kinase, and 0.01 units or more, preferably 0.01 to 100 units // of adenylate kinase, and added at 20 ° C or more. The reaction can be carried out preferably at 30 to 40 ° C. for about 1 to 50 hours with stirring as necessary.
- the ATP thus prepared can be isolated and purified by known methods.c Also, in a method for producing a compound using an enzyme reaction consuming ATP, The compound can be produced by reacting AMP with the above-mentioned polyphosphate kinase, adenylate kinase and ATP produced by reacting polyphosphoric acid to the enzyme reaction to supply the compound to the enzyme reaction. . In particular, in a method for producing a compound using an enzymatic reaction that consumes ATP, it is possible to carry out the reaction while regenerating ATP using AMP and / or ADP generated by the enzymatic reaction as a raw material.
- the target compound can be specifically produced, for example, galactose-1-phosphate synthesis system using galactokinase, UDP synthesis system using UMP kinase, phosphocollage using corin kinase. It can be applied to any enzymatic reaction that consumes ATP, such as a synthesis system.
- reaction conditions for such an ATP synthesis system and the enzymatic reaction may be appropriately determined by a small-scale test, and the target compound can be isolated and purified by a known method.
- Chromosomal DNA of E. coli K12 strain JM109 was prepared by the method of Saito and Miura (Biochim. Biophys. Acta., 72, 619 (1963)). This Using DNA as a template, the following two primers, DNA, were synthesized in a conventional manner, and the E. coli polyphosphate kinase (ppk) gene was amplified by PCR.
- Amplification of the ppk gene by PCR was performed in a reaction mixture of 10 (5 OmM chloride chloride, 10 mM Tris-HCl (pH 8.3), 1.5 mM magnesium chloride, 0.001% gelatin , Temperate DNA 0.1 lg, Primer DNA (A) (B) 0.2 ⁇ M each, Ampli Taq DNA polymerase 2.5 units) were replaced with Perkin-ElmerCetus Instrume. Thermal denaturation (94 ° C, 1 minute), annealing (55 ° C, 1.5 minutes), polymerase reaction (72, 1.5 Min) was repeated 25 times.
- the reaction solution was treated with a mixture of phenol Z-cloth form (1: 1), and the DNA was precipitated by adding twice the volume of ethanol to the water-soluble fraction.
- the DNA collected by precipitation was separated by agarose gel electrophoresis according to the method described in the literature (Molecular cloning. Supra), and a DNA fragment equivalent to Okb was purified.
- the DNA was cleaved with restriction enzymes NcoI and BamHI, and plasmid pTrc99A (obtained from Pharmacia Biotech), also digested with restriction enzymes NcoI and BamHI, and T4 DNA ligase Was connected using Escherichia coli JM109 was transformed using the ligation reaction solution, and plasmid pTrc-PPK was isolated from the obtained ampicillin-resistant transformant.
- pTr c-PPK is obtained by inserting an NcoI-BamHI DNA fragment containing the Escherichia coli ppk gene into the NcoI-BamHI cleavage site downstream of the trc promoter of pTrc99A.
- Escherichia coli JM109 carrying plasmid pTrc-Ppk was inoculated into 2XYT medium 30 containing 10OigZ ⁇ ampicillin, and cultured with shaking. Once at the 4 X 1 0 3 bacteria to a final concentration of 1 mM to the culture solution
- the specific activity of the polyphosphate kinase in the crude enzyme solution was 0.19 unit / mg protein, which was the specific activity of the control bacterium (E. coli JM109 bacterium harboring pTrc99A). 0.18 units (Zmg protein).
- the crude enzyme solution was fractionated using DEAE Toyopearl 6.5 M (Toy Corporation) with a concentration gradient of 0 to 0.5 M Na to obtain a polyphosphate kinase fraction. This fraction was used as a polyphosphate kinase enzyme preparation.
- the specific activity of polyphosphate kinase in this enzyme preparation was 0.6 unit Zmg protein.
- the unit (unit) of polyphosphate kinase activity in the present invention is measured and calculated by the following method. That is, the enzyme preparation was added to a 25 mM Tris-HCl buffer (pH 7.8) containing 5 mM magnesium chloride, 10 OmM ammonium sulfate, 5 mM ADP, and polyphosphoric acid (100 as inorganic phosphoric acid). Te, 3 7 ° to carry out the reaction by incubating at C, and ⁇ in the reaction solution with 1 0 0 ° C, 1 minute annealing c high-performance liquid ⁇ Matogurafi one to stop the reaction by (HP LC) Quantify the activity to produce 1 mo ⁇ e of ATP per minute at 37 ° C. O
- Chromosomal DNA of Escherichia coli 12 strain JM109 was prepared by the method of Saito and Miura (Biochim. Biophys. Acta., 72, 619 (1963)).
- DNA was synthesized according to a conventional method, and the Escherichia coli adduct kinase (adk) gene was amplified by PCR.
- Amplification of the adk gene by PCR was performed in a reaction mixture of 100 mM (50 mM chloride, 10 mM Tris-HCl (pH 8.3), 1.5 raM magnesium chloride, 0.001% 0.1 g of gelatin and temperate DNA, 0.1 M of each of primer DNA (A) and (B), 2.5 M of Amp1i Taq DNA polymerase (2.5 units) were added to Perkin-Elmer C Thermal denaturation (94 min., 1 min.), annealing (56 ° C, 1.0 min.), polymerization (72 min.) were performed using DNA Thermal Cyc 1 er manufactured by etus International. And 3.0 minutes) were repeated 25 times.
- the reaction solution was treated with a mixture of funinol Z-cloth form (1: 1), and DNA was precipitated by adding twice the volume of ethanol to the water-soluble fraction.
- the DNA collected by precipitation was separated by agarose gel electrophoresis according to the method described in the literature (Molecular cloning. Supra), and a DNA fragment equivalent to Okb was purified.
- the DNA was digested with the restriction enzymes BamHI and HindIII, and the plasmid pUC18 (obtained from Takara Shuzo) and T4 DNA digested with the restriction enzymes BamHI and HindIII. Ligation was performed using ligase.
- pUC-ADK Escherichia coli JM109 using ligation reaction solution And the plasmid pUC-ADK was isolated from the resulting ampicillin-resistant transformant.
- pUC-ADK is obtained by inserting a BamHI-Hind UI DNA fragment containing the E. coli adk gene into the BamHI-HindII cleavage site downstream of the lac promoter overnight in pUC18.
- Escherichia coli JM109 carrying plasmid pUC—ADK was inoculated into 300 XYT medium containing 100 Ozg / ampicillin and cultured at 37 ° C with shaking. Once at the 4 X 1 0 8 bacteria Bruno, to a final concentration of 1 mM to the culture solution
- IPTG was added, and shaking culture was continued at 30 ° C. for 5 hours. After completion of the culture, the cells were collected by centrifugation (9,000 X g., 10 minutes), and the buffer of 60 ⁇ (50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0 mM 1% Triton X—100, 0.2 mg Z ⁇ rhizodium). After incubating at 37 ° C for 1 hour, the cells were sonicated to disrupt the cells, and the cells were removed by centrifugation (20,000 X g., 10 minutes).
- the supernatant fraction thus obtained was dialyzed against 5 OmM Tris-HCl (pH 7.8) containing 5 mM magnesium chloride and 1 mill 2-mercaptoethanol to obtain a crude enzyme solution.
- the specific activity of adenylate kinase in the crude enzyme solution was 134 units of Zmg protein, and the specific activity of the control bacterium (E. coli JM109 carrying pUC18) (1.9 units / unit). mg protein).
- the crude enzyme solution DEAE preparative Yono, 0 - fractionated by gradient 0 ⁇ 0. 5 M Na C _ ⁇ with Le 6 5 0 M (DOO one source i (Inc.)), Ade two rate Fractions with kinase activity were collected.
- This fraction was used as an adenylate kinase enzyme preparation.
- the specific activity of polyphosphate kinase in this enzyme preparation was 344 unit Zmg protein.
- the unit (unit) of the adenylate kinase activity in the present invention was also measured and calculated by the following method. That is, an enzyme preparation was added to 50 mM Tris-HCl buffer (pH 7.8) containing 5 mM magnesium chloride, 5 mM ATP, and 5 mM AMP. The reaction is carried out by keeping the temperature at 37 ° C, and the reaction is stopped by heat treatment at 100 ° C for 1 minute. Quantify ADP in the reaction solution using HP LC, and define the activity to produce 2 / mo ⁇ e of ADP per minute at 37 ° C as 1 unit (unit).
- PPK Polyphosphate kinase
- ADK Adenylate kinase
- AMP phosphorylation does not occur when a crude enzyme solution prepared from normal E. coli (JM109 CpUC18)) is mixed with polyphosphoric acid kinase, but adenylate kinase-producing strain ( When the crude enzyme solution prepared from JM109CpUC-ADK)) was mixed with polyphosphate kinase, a marked AMP phosphorylation reaction occurred. From the above, it is clear that co-presence of polyphosphate kinase and adenylate kinase causes AMP phosphorylation.
- the cells were collected by centrifugation (9,000 X g, 10 minutes), and a buffer of 6 ⁇ (50 mM Tris-HCl (pH 7.5), 5 mM EDTA, 0 mM 1% Triton X—100, 0.2 mg Z7 ⁇ ribzyme). After incubation at 37 ° C for 1 hour, sonication was performed to disrupt the cells, and centrifugation (20,000 X g,
- the unit (unit) of galactokinase activity was measured and calculated by the following method. Add enzyme preparation to 10 OmM Tris-HCl buffer (pH 7.8) containing 5 mM magnesium chloride, 1 OmM ATP, and 10 mM galactose.
- the reaction is carried out by keeping the temperature at 37 ° C, and the reaction is stopped by heat treatment at 100 T: 1 minute.
- the 1-phosphoric acid is quantified, and the activity to produce 1 mo ⁇ e of galactose- 1-phosphoric acid per minute at 37 ° C is defined as 1 unit (unit).
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Procédé de production d'adénosine 5'-triphosphate (ATP) par mise en réaction d'adénosine 5'-monophosphate (AMP) avec une polyphosphate kinase, une adénylate kinase et un acide phosphorique. Ledit procédé permet de produire de l'ATP facilement et de manière peu onéreuse.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP54545098A JP3764755B2 (ja) | 1997-04-18 | 1998-04-15 | 「アデノシン5’−三リン酸の製造法及びその応用」 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP11627297 | 1997-04-18 | ||
JP9/116272 | 1997-04-18 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998048031A1 true WO1998048031A1 (fr) | 1998-10-29 |
Family
ID=14682979
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1998/001711 WO1998048031A1 (fr) | 1997-04-18 | 1998-04-15 | Procede de production d'adenosine 5'-triphosphate et utilisation de ladite substance |
Country Status (2)
Country | Link |
---|---|
JP (1) | JP3764755B2 (fr) |
WO (1) | WO1998048031A1 (fr) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001053513A1 (fr) * | 2000-01-17 | 2001-07-26 | Satake Corporation | Systemes et procede de reaction de regeneration atp permettant d'examiner le nucleotide d'adenine, procede de detection d'arn et procede d'amplification d'atp |
EP1652934A1 (fr) * | 2003-07-29 | 2006-05-03 | Japan Science and Technology Agency | Procede ameliore d'amplification de l'atp et son utilisation |
WO2006095696A1 (fr) * | 2005-03-10 | 2006-09-14 | Bussan Nanotech Research Institute, Inc. | Methode de detection de l’adenosine triphosphate et reactif de detection utilise |
JP2009050264A (ja) * | 2002-05-29 | 2009-03-12 | Yamasa Shoyu Co Ltd | 新規なポリリン酸:ampリン酸転移酵素 |
EP2100956A1 (fr) | 2005-01-25 | 2009-09-16 | Yamasa Corporation | Procédé de synthèse enzymatique de 3'-phosphoadenosine-5'-phophosulfate |
JP2020504615A (ja) * | 2016-12-30 | 2020-02-13 | エヌティーエックスバイオ,エルエルシー | 新規無機リン酸ベースエネルギー再生機能を備えた無細胞発現系 |
US12227778B2 (en) | 2016-12-30 | 2025-02-18 | Nature's Toolbox, Inc. | Cell-free expression system having novel inorganic polyphosphate-based energy regeneration |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5800218B2 (ja) * | 2011-07-20 | 2015-10-28 | 国立大学法人広島大学 | Atpの製造方法およびその利用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4882087A (fr) * | 1972-02-07 | 1973-11-02 | ||
JPS57166992A (en) * | 1981-04-08 | 1982-10-14 | Seitetsu Kagaku Co Ltd | Preparation of adenosine-5'-triphosphate |
JPS59106296A (ja) * | 1982-12-09 | 1984-06-19 | Kazutomo Imahori | 複合酵素法による生理活性物質の製造法 |
-
1998
- 1998-04-15 WO PCT/JP1998/001711 patent/WO1998048031A1/fr active Application Filing
- 1998-04-15 JP JP54545098A patent/JP3764755B2/ja not_active Expired - Lifetime
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4882087A (fr) * | 1972-02-07 | 1973-11-02 | ||
JPS57166992A (en) * | 1981-04-08 | 1982-10-14 | Seitetsu Kagaku Co Ltd | Preparation of adenosine-5'-triphosphate |
JPS59106296A (ja) * | 1982-12-09 | 1984-06-19 | Kazutomo Imahori | 複合酵素法による生理活性物質の製造法 |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001053513A1 (fr) * | 2000-01-17 | 2001-07-26 | Satake Corporation | Systemes et procede de reaction de regeneration atp permettant d'examiner le nucleotide d'adenine, procede de detection d'arn et procede d'amplification d'atp |
JP2009050264A (ja) * | 2002-05-29 | 2009-03-12 | Yamasa Shoyu Co Ltd | 新規なポリリン酸:ampリン酸転移酵素 |
US7745160B2 (en) | 2003-07-29 | 2010-06-29 | Japan Science And Technology Agency | Method of amplifying ATP and use thereof |
EP1652934A4 (fr) * | 2003-07-29 | 2008-03-12 | Japan Science & Tech Agency | Procede ameliore d'amplification de l'atp et son utilisation |
EP1652934A1 (fr) * | 2003-07-29 | 2006-05-03 | Japan Science and Technology Agency | Procede ameliore d'amplification de l'atp et son utilisation |
US8003341B2 (en) | 2003-07-29 | 2011-08-23 | Japan Science And Technology Agency | Method of amplifying ATP and use thereof |
EP2100956A1 (fr) | 2005-01-25 | 2009-09-16 | Yamasa Corporation | Procédé de synthèse enzymatique de 3'-phosphoadenosine-5'-phophosulfate |
US8728789B2 (en) | 2005-01-25 | 2014-05-20 | Yamasa Corporation | DNA fragment encoding a polyphosphate-driven nucleoside 5′-diphosphate kinase polypeptide |
US9193958B2 (en) | 2005-01-25 | 2015-11-24 | Yamasa Corporation | Method of enzymatically synthesizing 3′-phosphoadenosine-5′-phosphosulfate |
WO2006095696A1 (fr) * | 2005-03-10 | 2006-09-14 | Bussan Nanotech Research Institute, Inc. | Methode de detection de l’adenosine triphosphate et reactif de detection utilise |
JP2020504615A (ja) * | 2016-12-30 | 2020-02-13 | エヌティーエックスバイオ,エルエルシー | 新規無機リン酸ベースエネルギー再生機能を備えた無細胞発現系 |
US11136586B2 (en) | 2016-12-30 | 2021-10-05 | Ntxbio, Llc | Cell-free expression system having novel inorganic polyphosphate-based energy regeneration |
US12227778B2 (en) | 2016-12-30 | 2025-02-18 | Nature's Toolbox, Inc. | Cell-free expression system having novel inorganic polyphosphate-based energy regeneration |
Also Published As
Publication number | Publication date |
---|---|
JP3764755B2 (ja) | 2006-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4505011B2 (ja) | 3’−ホスホアデノシン−5’−ホスホ硫酸の酵素合成法 | |
US20210246476A1 (en) | Biosynthesis of preparing nicotinamide mononucleotide and derivatives thereof | |
WO1998048031A1 (fr) | Procede de production d'adenosine 5'-triphosphate et utilisation de ladite substance | |
WO2003100056A1 (fr) | Nouvelle enzyme polyphosphate :amp phosphotransferase | |
US6040158A (en) | Process for preparing sugar nucleotide | |
JP5140242B2 (ja) | Cmp−n−アセチルノイラミン酸の製造法 | |
JP4173815B2 (ja) | 2’−デオキシグアノシンの製造法 | |
CA2392463C (fr) | Nouvelle utilisation de l'uridine-diphosphate-glucose 4-epimerase | |
KR100481763B1 (ko) | 우리딘 이인산-엔-아세틸글루코사민의 제조법 | |
JP5068956B2 (ja) | デオキシリボヌクレオシド一リン酸からのデオキシリボヌクレオシド三リン酸の製造方法 | |
KR100680765B1 (ko) | 3'-아미노-2',3'-디데옥시구아노신의 제조 방법 | |
JP2002085087A (ja) | シチジン5’−トリリン酸の製造法及びその応用 | |
WO1999049073A1 (fr) | Procede de production de cytidine 5'-diphosphate choline | |
JP2001169797A (ja) | S―アデノシル−l−メチオニンの酵素的製造法 | |
JP2000041695A (ja) | S―アデノシル−l−メチオニンの酵素的製造法 | |
JP4010996B2 (ja) | デオキシヌクレオシド5’−モノリン酸の製造法 | |
CN116479074A (zh) | 一种由GDP-Mannose合成稀有糖类核苷酸的方法 | |
JP2000217593A (ja) | シチジン5’−トリリン酸の酵素的製造法およびその応用 | |
JP2999256B2 (ja) | イノシングアノシンキナーゼ | |
WO1999024600A1 (fr) | Procede servant a preparer un nucleotide de sucre | |
KR19990074792A (ko) | 유전자 재조합 미생물에 의한 5'-구아닐산의 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN JP KR US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: CA |